{
  "data": {
    "id": "stat_5G05C4071390GSGWEZ14J67AN3",
    "url": "https://statorigin.org/stat/stat_5G05C4071390GSGWEZ14J67AN3",
    "indicator": {
      "slug": "ctgov-adc-trial-starts",
      "name": "Antibody-drug conjugate trial starts",
      "definition": "Count of interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count."
    },
    "industry": [
      {
        "slug": "pharmaceuticals",
        "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
        "isic": "C21",
        "is_primary": true
      }
    ],
    "region": {
      "code": "US",
      "name": "United States",
      "type": "country"
    },
    "period": {
      "start": "2025-01-01",
      "end": "2025-12-31",
      "type": "year"
    },
    "value": 144,
    "value_text": "144 studies",
    "unit": "count",
    "currency": null,
    "scale": "1",
    "value_type": "actual",
    "source": {
      "org": "ClinicalTrials.gov (U.S. National Library of Medicine)",
      "org_short_name": "ClinicalTrials.gov",
      "org_url": "https://clinicaltrials.gov",
      "org_tier": 1,
      "document_title": "ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States",
      "document_url": "https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2025-01-01%2C2025-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId",
      "document_type": "dataset",
      "locator": "totalCount field of the API response. Query: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States.",
      "quote": "{\"totalCount\":144,\"studies\":[",
      "published_date": null,
      "accessed_at": "2026-09-27",
      "license": "public-domain",
      "url_status": "ok",
      "self_reported": false
    },
    "verification": "verified",
    "verified_by": "pipeline:ctgov-api-totalcount-verified",
    "verified_at": "2026-09-27T12:00:00.000Z",
    "confidence": 0.95,
    "is_secondhand": false,
    "supersedes": "stat_KZB814PSRBZ6DHB59S4WCR6HCM",
    "superseded_by": null,
    "is_current": true,
    "citation": {
      "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2025). ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.term=%22antibody-drug%20conjugate%22%20OR%20%22antibody%20drug%20conjugate%22%20OR%20deruxtecan%20OR%20vedotin%20OR%20govitecan%20OR%20emtansine%20OR%20ozogamicin%20OR%20tesirine%20OR%20mafodotin%20OR%20soravtansine%20OR%20tirumotecan%20OR%20rezetecan%20OR%20%22SKB264%22%20OR%20%22SHR-A1811%22%20OR%20%22BL-B01D1%22%20OR%20izalontamab%20OR%20disitamab%20OR%20%22trastuzumab%20deruxtecan%22%20OR%20DS-8201%20OR%20T-DXd%20OR%20SHR-A1811%20OR%20%22trastuzumab%20rezetecan%22%20OR%20%22sacituzumab%20tirumotecan%22%20OR%20SKB264%20OR%20sac-TMT%20OR%20MK-2870%20OR%20%22disitamab%20vedotin%22%20OR%20RC48%20OR%20%22sacituzumab%20govitecan%22%20OR%20IMMU-132%20OR%20%22enfortumab%20vedotin%22%20OR%20BL-B01D1%20OR%20%22datopotamab%20deruxtecan%22%20OR%20Dato-DXd%20OR%20DS-1062&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2025-01-01%2C2025-12-31%5D%20AND%20AREA%5BLocationCountry%5D%22United%20States%22&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_5G05C4071390GSGWEZ14J67AN3",
      "bibtex": "@misc{clinicaltrialsgo2025ctgovj67an3,\n  author       = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n  title        = {ClinicalTrials.gov study count: Interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States},\n  year         = {2025},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_5G05C4071390GSGWEZ14J67AN3},\n  note         = {Original source: https://clinicaltrials.gov/api/v2/studies?query.term=\\%22antibody-drug\\%20conjugate\\%22\\%20OR\\%20\\%22antibody\\%20drug\\%20conjugate\\%22\\%20OR\\%20deruxtecan\\%20OR\\%20vedotin\\%20OR\\%20govitecan\\%20OR\\%20emtansine\\%20OR\\%20ozogamicin\\%20OR\\%20tesirine\\%20OR\\%20mafodotin\\%20OR\\%20soravtansine\\%20OR\\%20tirumotecan\\%20OR\\%20rezetecan\\%20OR\\%20\\%22SKB264\\%22\\%20OR\\%20\\%22SHR-A1811\\%22\\%20OR\\%20\\%22BL-B01D1\\%22\\%20OR\\%20izalontamab\\%20OR\\%20disitamab\\%20OR\\%20\\%22trastuzumab\\%20deruxtecan\\%22\\%20OR\\%20DS-8201\\%20OR\\%20T-DXd\\%20OR\\%20SHR-A1811\\%20OR\\%20\\%22trastuzumab\\%20rezetecan\\%22\\%20OR\\%20\\%22sacituzumab\\%20tirumotecan\\%22\\%20OR\\%20SKB264\\%20OR\\%20sac-TMT\\%20OR\\%20MK-2870\\%20OR\\%20\\%22disitamab\\%20vedotin\\%22\\%20OR\\%20RC48\\%20OR\\%20\\%22sacituzumab\\%20govitecan\\%22\\%20OR\\%20IMMU-132\\%20OR\\%20\\%22enfortumab\\%20vedotin\\%22\\%20OR\\%20BL-B01D1\\%20OR\\%20\\%22datopotamab\\%20deruxtecan\\%22\\%20OR\\%20Dato-DXd\\%20OR\\%20DS-1062\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\%20AND\\%20AREA\\%5BStartDate\\%5DRANGE\\%5B2025-01-01\\%2C2025-12-31\\%5D\\%20AND\\%20AREA\\%5BLocationCountry\\%5D\\%22United\\%20States\\%22\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}"
    },
    "updated_at": "2026-09-27T01:11:36.992Z",
    "contested_by": [],
    "related": []
  },
  "meta": {
    "attribution": "Data from StatOrigin (https://statorigin.org), CC BY 4.0. Attribution required.",
    "license": "https://creativecommons.org/licenses/by/4.0/",
    "docs": "https://statorigin.org/docs/api",
    "total": 1
  }
}